Menu Close

Baker Tilly Wealth Management LLC Buys 209 Shares of Humana Inc. (NYSE:HUM)

view original post

Baker Tilly Wealth Management LLC raised its stake in shares of Humana Inc. (NYSE:HUM) by 26.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 987 shares of the insurance provider’s stock after acquiring an additional 209 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Humana were worth $384,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HUM. FMR LLC lifted its stake in Humana by 18.7% during the 2nd quarter. FMR LLC now owns 10,241,494 shares of the insurance provider’s stock valued at $4,534,114,000 after acquiring an additional 1,612,251 shares in the last quarter. Amundi bought a new position in Humana during the 2nd quarter valued at $393,330,000. First Trust Advisors LP lifted its stake in Humana by 186.1% during the 2nd quarter. First Trust Advisors LP now owns 690,050 shares of the insurance provider’s stock valued at $305,499,000 after acquiring an additional 448,859 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Humana by 87.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 335,905 shares of the insurance provider’s stock valued at $148,712,000 after acquiring an additional 157,127 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Humana by 2.9% during the 2nd quarter. State Street Corp now owns 5,624,088 shares of the insurance provider’s stock worth $2,493,769,000 after purchasing an additional 156,025 shares during the period. Institutional investors and hedge funds own 91.75% of the company’s stock.

In other news, CEO Bruce D. Broussard sold 50,006 shares of the business’s stock in a transaction dated Friday, November 5th. The stock was sold at an average price of $454.70, for a total transaction of $22,737,728.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.40% of the stock is owned by insiders.

HUM stock opened at $460.54 on Monday. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $59.20 billion, a PE ratio of 22.24, a PEG ratio of 1.63 and a beta of 0.92. Humana Inc. has a twelve month low of $370.22 and a twelve month high of $475.44. The stock has a 50-day simple moving average of $447.64 and a two-hundred day simple moving average of $432.42.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 3rd. The insurance provider reported $4.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.61 by $0.22. The business had revenue of $20.70 billion during the quarter, compared to analyst estimates of $20.91 billion. Humana had a return on equity of 14.95% and a net margin of 3.30%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.08 EPS. On average, equities research analysts anticipate that Humana Inc. will post 20.52 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 28th. Shareholders of record on Friday, December 31st will be issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, December 30th. Humana’s payout ratio is presently 13.52%.

A number of equities research analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft lifted their target price on Humana from $427.00 to $456.00 and gave the stock a “hold” rating in a research note on Tuesday, November 9th. Cowen assumed coverage on Humana in a research note on Thursday, September 9th. They set an “outperform” rating and a $479.00 target price on the stock. Barclays lifted their target price on Humana from $500.00 to $540.00 and gave the stock an “overweight” rating in a research note on Thursday, November 4th. Morgan Stanley cut Humana from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $559.00 to $530.00 in a research note on Thursday, December 16th. Finally, Credit Suisse Group lifted their target price on Humana from $500.00 to $513.00 and gave the stock an “outperform” rating in a research note on Thursday, November 4th. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Buy” and a consensus price target of $500.15.

Humana Profile

Humana Inc engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts.

Featured Article: What is insider trading?

Want More Great Investing Ideas?